Latest Breaking News On - தெளிவு ஒஸாவ - Page 1 : comparemela.com

After their startups were acquired, 3 biotech executives try a second act with San Diego s 858 Therapeutics

After their startups were acquired, 3 biotech executives try a second act with San Diego s 858 Therapeutics
sandiegouniontribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegouniontribune.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSan diegoGretchen bainJeffrey staffordBristol myers squibbAli behbahaniClare ozawaEnterprise associatesQuanticel pharmaceuticalsAmira pharmaceuticalsJames vealJecure therapeuticsNew york based gotham therapeuticsNew york cityCormorant asset management

Lycia Therapeutics Announces $70 Million Series B Financing

Lycia Therapeutics Announces $70 Million Series B Financing
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Al iskandariyahTim andersonEli lillyWilliamj rieflinLiz meloneClare ozawaLaurent fischerTom woiwodeCarolyn bertozziJeremy caldwellAdverum biotechnologies incHead of researchLycia therapeutics incRedmile groupBiopharmaceuticals incTherapeutics inc

Stablix lands on stable footing with $63M series A for protein stabilization efforts

Stablix Therapeutics launches today with a $63 million series A to bankroll work on protein stabilization in the hopes of treating rare diseases, cancer and immunological disorders.

Al iskandariyahUnited kingdomCarlo rizzutoChris robertsScott kannerHenry colecraftClare ozawaKronos bioChris dinsmoreAndrew turnbullOxford target discovery institute professor benedikt kesslerEnterprise associatesCancer research united kingdomColumbia universityAlexandria real estate equitiesStablix therapeutics

Capsida Biotherapeutics Debuts with $140 Million of Capital

Capsida Biotherapeutics Debuts with $140 Million of Capital - Versant, Westlake Village BioPartners launch next-generation gene therapy company with $50 million Series A - - Collaboration with AbbVie provides $90 million in up front and equity investment capital to create tissue-targeted gene therapies for three CNS disease targets - News provided by Share this article Share this article THOUSAND OAKS, Calif., April 29, 2021 /PRNewswire/ Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases. In addition to a $50 million Series A commitment from the two firms, Capsida also announced a multi-year strategic collaboration and option agreement with AbbVie that provides $90 million in up front and equity investment capital in addit

Thousand oaksUnited statesEric karranLos angelesBeth seidenbergRobert cuddihyViviana gradinaruCapsida biotherapeuticsClare ozawaChrissy chen institute for neuroscience at caltechCapsida biotherapeutics incHeritage medical research institute investigatorWestlake village biopartnersBiological engineeringCellular neuroscienceChrissy chen institute

Versant Ventures Raises $950 Million Across Three Vehicles

Versant Ventures Raises $950 Million Across Three Vehicles $140 million companion fund to boost selected early high-performers $250 million opportunity fund for later-stage rounds Versant Ventures today announced $950 million in additional capital allocated across a platform of three separate vehicles. These included Versant Venture Capital VIII, a $560 million primary global biotech fund; Versant Voyageurs II, a $140 million booster fund; and Versant Vantage II, a $250 million later-stage opportunity fund. All three funds exceeded their initial targets and were heavily oversubscribed. The capital from existing investors and a select number of new top-tier limited partners will support Versant s highly successful biotech investment strategy and portfolio construction model.

United statesAlex maywegKostenloser wertpapierhandelSteve edelsonJerel davisBrad bolzonTom woiwodeClare ozawaVersant venture capitalVersant voyageursVersant vantageDiscovery enginesNorth americaVersant venturesஒன்றுபட்டது மாநிலங்களில்ஸ்டீவ் எடெல்சன்